Published in Pharma Law Weekly, January 11th, 2005
The findings, which were published in Cancer Cell, suggest that drugs that cut off melanoma cells' supply of the protein, called CDK2, might curb the growth of the dangerous skin cancer in patients, and with relatively low toxicity.
In theory, such a drug would leave normal cells unharmed and have many fewer side effects compared to standard chemotherapy.
Working with melanoma cells grown in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly